Roundtable Discussion: Balancing Fat Loss, Muscle Preservation, & Metabolic Health to Optimise Combination Therapies
- Integrating myostatin/activin inhibitors with GLP-1 agonists to preserve metabolic health and enhance long-term patient outcomes
- Leveraging biomarkers & phenotyping to guide patient stratification for combination therapies to identify responders to specific mechanisms
- Designing adaptive trials for multi targeted therapies to enable dosing optimisation and combination ratios for improved efficacy and tolerability